Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Recruiting · NCT04038502 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fanconi anemia complementation group D1, Fanconi anemia complementation group N, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, central nervous system malformation, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-09-17 | NCT04038502 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| VA Office of Research and Development | 472 |
18 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.